Julphar launches Sojourn® (Sevoflurane) for general anesthesia in KSA

As part of its commitment to contribute to a better healthcare in the region and following its partnership with the American manufacturer of generic, Piramal Critical Care, to market and distribute Sojourn® (Sevoflurane) in Saudi Arabia, Julphar has launched the general inhalational anesthetic Sojourn in the country.

The Sojourn launch event took place on May 7th at the Intercontinental Hotel in Istanbul, Turkey. On that occasion, Julphar invited Dr Jan Hendrickx, anesthesiologist from the Onze-Lieve-Vrouwziekenhuis (OLV) Hospital of Belgium who addressed an audience of over 20 top anesthesia consultants from Saudi Arabia to discuss the current concepts and the newest existing technics of inhalation anesthesia that help reduce complications during the patient’s awakening and recovery.

“Anesthesia is a new segment of investment for Julphar and it represents an opportunity for the company to stick with its primary mission to improve people’s quality of life in the Middle East”, said Dr Hosam Badr, Marketing Director at Julphar. “We are the first company to commercialize and distribute Sevoflurane generic in Saudi Arabia, our biggest market. Our goal is to be thoroughly involved in the Saudi healthcare community, and Sojourn® launch is part of our plan to enrich our portfolio in the country and meet the needs of patients and Healthcare Professionals (HCP’s).”

Sojourn® (Sevoflurane) is manufactured by Piramal Critical Care, and is used in the induction and maintenance of general anesthesia for adults and pediatric patients.